Gabapentin, Phenobarbital, Diazepam, and Lorazepam for the Treatment of Alcohol Withdrawal: Clinical Effectiveness and Guidelines
Authors: Diksha Kumar, Charlene Argáez


Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca
Research Questions

1. What is the clinical effectiveness of gabapentin, phenobarbital, diazepam, and lorazepam for the management of individuals with alcohol withdrawal?

2. What are the evidence-based guidelines regarding the management of individuals with alcohol withdrawal in the emergency department?

3. What are the evidence-based guidelines regarding the provision of addiction services to vulnerable populations with alcohol withdrawal during the coronavirus pandemic?

Key Findings

Two systematic reviews and eleven non-randomized studies were identified regarding the clinical effectiveness of gabapentin, phenobarbital, diazepam, and lorazepam for the management of individuals with alcohol withdrawal. Four evidence-based guidelines were identified regarding the management of individuals with alcohol withdrawal in the emergency department. No relevant evidence-based guidelines were identified regarding the provision of addiction services to vulnerable populations with alcohol withdrawal during the coronavirus pandemic.

Methods

A limited literature search was conducted by an information specialist on key resources including PubMed, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concepts were the use of gabapentin, phenobarbital, diazepam, and lorazepam for addiction services, and COVID-19. No filters were applied to limit the retrieval by study type for question #1. For questions #2 and #3, a guidelines filter was applied. The search was also limited to English language documents published between January 1, 2015 and June 2, 2020.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

<table>
<thead>
<tr>
<th></th>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td>Individuals with alcohol withdrawal</td>
<td>Q1: Gabapentin; phenobarbital; diazepam; lorazepam</td>
<td>Q1: Any combination of gabapentin, phenobarbital, diazepam, or lorazepam</td>
<td>Q1: Clinical effectiveness (e.g.: symptom severity)</td>
</tr>
<tr>
<td>Q2</td>
<td>Individuals presenting to the emergency department with alcohol withdrawal</td>
<td>Q2: Any intervention for managing alcohol withdrawal (e.g., pharmacologic treatments, non-pharmacologic treatments)</td>
<td>Q2-Q3: Not applicable</td>
<td></td>
</tr>
<tr>
<td>Q3</td>
<td>Vulnerable populations with alcohol withdrawal (e.g., those in need of supported self-isolation)</td>
<td>Q3: Addiction services for managing alcohol withdrawal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SUMMARY OF ABSTRACTS

Gabapentin, Phenobarbital, Diazepam, and Lorazepam for the Treatment of Alcohol Withdrawal

Study Designs

- intensive care admissions
- withdrawal seizures
- mortality
- safety [e.g., rates of adverse events]

Q2-Q3: Recommendations regarding best practices (e.g.:
- Treatment protocols and advice for drug selection
- Recommended safeguards
- Guidance relating to how medications should be dispensed and monitored,
- Discharge and admission protocols [e.g., using the Prediction of Alcohol Withdrawal Severity Scale]
- Guidance relating to how isolation practices can be implemented)

Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, evidence-based guidelines

Results

Two systematic reviews\(^1\)\(^-\)\(^2\) and eleven non-randomized studies\(^3\)\(^-\)\(^{13}\) were identified regarding the clinical effectiveness of gabapentin, phenobarbital, diazepam, and lorazepam for the management of individuals with alcohol withdrawal. Four evidence-based guidelines\(^1\(^4\)\(^-\)\(^{17}\) were identified regarding the management of individuals with alcohol withdrawal in the emergency department. No relevant health technology assessments or randomized controlled trials were identified.

References of potential interest that did not meet the inclusion criteria are provided in the appendix.

Overall Summary of Findings

Two systematic reviews\(^1\)\(^-\)\(^2\) and eleven non-randomized studies\(^3\)\(^-\)\(^{13}\) were identified regarding the clinical effectiveness of gabapentin, phenobarbital, diazepam, and lorazepam for the management of individuals with alcohol withdrawal.

Two systematic reviews\(^1\)\(^-\)\(^2\) and seven non-randomized studies\(^7\)\(^-\)\(^{13}\) compared barbiturates to benzodiazepines for the treatment of alcohol withdrawal syndrome (AWS). The authors of one systematic review\(^1\) and four non-randomized studies\(^6\)\(^-\)\(^{11}\) found that patients treated with phenobarbital with or without concomitant benzodiazepine therapy experienced similar rates of intensive care unit (ICU) admission,\(^1\(^9\)\(^-\)\(^{11}\) median ICU length of stay,\(^8\) and hospital length of stay\(^1\(^1\)\(^-\)\(^0\) as patients treated with benzodiazepines alone. The second systematic review\(^2\) found that barbiturates alone or in combination with benzodiazepines are as effective as benzodiazepines, with similar tolerability and safety profiles in an acute care setting. Patients treated with a combination of benzodiazepines and phenobarbital also had a similar improvement in severity of alcohol withdrawal and duration of withdrawal symptoms as patients treated with benzodiazepines alone.\(^1\(^3\) However, Tidwell et al.\(^1\(^2\) found that patients treated with phenobarbital had significantly shorter ICU and hospital stays compared to patients treated with benzodiazepines. Similarly, Ibarra et al.\(^7\) found that significantly more patients in the lorazepam and phenobarbital treatment group were discharged within a three-day period compared to patients in the lorazepam control group.

The authors of one non-randomized study\(^3\) compared frontloading lorazepam to diazepam in patients with AWS. There was no significant difference among the groups in the mean
change in severity of alcohol withdrawal following treatment.\(^3\) Patients frontloaded with lorazepam had a significantly increased incidence of delirium in the intensive care unit.\(^3\)

The authors of three non-randomized studies\(^4\)–\(^6\) compared combination gabapentin and benzodiazepine therapy with benzodiazepines alone for the treatment of AWS. The authors of two of these non-randomized studies\(^4\)–\(^6\) found similar outcomes between groups in terms of decrease in severity of alcohol withdrawal symptoms,\(^4\) duration of alcohol withdrawal protocol,\(^6\) and length of hospital stay.\(^6\) However, Levine et al.\(^5\) found that patients in the gabapentin treatment group had significantly lower levels of alcohol withdrawal symptoms on day three of hospitalization and shorter lengths of hospital stay compared to patients in the control group.

Four evidence-based guidelines\(^1\)–\(^4\),\(^1\)\(^4\)–\(^1\)\(^7\) were identified regarding the management of individuals with alcohol withdrawal in the emergency department. The guideline by Butt et al.\(^1\)\(^4\) recommends that older adults with symptoms of alcohol withdrawal should receive 24-hour care in intensive treatment or hospital settings if they are in poor general health, acutely suicidal, have dementia, are medically unstable, or need constant one-on-one monitoring.\(^1\)\(^4\) Older adults should be treated with a short-acting benzodiazepine such as lorazepam.\(^1\)\(^4\) The British Columbia Centre on Substance Abuse recommends that the Prediction of Alcohol Withdrawal Severity Scale be used to assess the risk of complications of alcohol withdrawal, and patients at high risk be treated with benzodiazepines in an inpatient setting.\(^1\)\(^5\) The National Institute for Health and Care Excellence recommends that patients with acute alcohol withdrawal in a hospital setting be treated with a benzodiazepine, carbamazepine, or clomethiazole and follow a symptom-triggered regimen.\(^1\)\(^6\) Guidelines from the Veteran Affairs and the Department of Defense recommend symptom-triggered therapy with benzodiazepines for the treatment of moderate to severe alcohol withdrawal.\(^1\)\(^7\) Carbamazepine, gabapentin, or valproic acid can be appropriate alternatives for managing mild to moderate alcohol withdrawal in patients for whom the risks associated with the use of benzodiazepines outweigh the benefits.\(^1\)\(^7\)

No relevant evidence-based guidelines were found regarding the provision of addiction services to vulnerable populations with alcohol withdrawal during the coronavirus pandemic; therefore, no summary can be provided.

**References Summarized**

**Health Technology Assessments**

No literature identified.

**Systematic Reviews and Meta-Analyses**


Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

**Lorazepam versus Diazepam**


**Benzodiazepines versus Gabapentin**


**Benzodiazepines versus Phenobarbital**


Guidelines and Recommendations


Appendix — Further Information

Previous CADTH Reports


Systematic Reviews and Meta-Analyses

Comparator Not Specified


Non-Randomized Studies

Alternative Population


Alternative Outcomes


Clinical Practice Guidelines – Unclear Methodology


Review Articles

